Impact of Internet-Based Pharmacy Care on Patient-Reported Outcomes in Congenital Heart Disease-Associated Pulmonary Hypertension in Yunnan, China.
X, L., L, F., W, W., M, Q., H, L., & T, L. (2026). Impact of Internet-Based Pharmacy Care on Patient-Reported Outcomes in Congenital Heart Disease-Associated Pulmonary Hypertension in Yunnan, China.. Journal of visualized experiments : JoVE. https://doi.org/10.3791/72056
X L, L F, W W, M Q, H L, T L. Impact of Internet-Based Pharmacy Care on Patient-Reported Outcomes in Congenital Heart Disease-Associated Pulmonary Hypertension in Yunnan, China.. Journal of visualized experiments : JoVE. 2026; doi: 10.3791/72056
X L, L F, W W, et al. Impact of Internet-Based Pharmacy Care on Patient-Reported Outcomes in Congenital Heart Disease-Associated Pulmonary Hypertension in Yunnan, China.[J]. Journal of visualized experiments : JoVE. 2026. DOI: 10.3791/72056.
@article{x2026,
author = {Li X and Fu L and Wu W and Qu M and Li H and Li T},
title = {Impact of Internet-Based Pharmacy Care on Patient-Reported Outcomes in Congenital Heart Disease-Associated Pulmonary Hypertension in Yunnan, China.},
journal = {Journal of visualized experiments : JoVE},
year = {2026},
doi = {10.3791/72056},
note = {PMID: 42612115},
}
TY - JOUR AU - Li X AU - Fu L AU - Wu W AU - Qu M AU - Li H AU - Li T TI - Impact of Internet-Based Pharmacy Care on Patient-Reported Outcomes in Congenital Heart Disease-Associated Pulmonary Hypertension in Yunnan, China. T2 - Journal of visualized experiments : JoVE PY - 2026 DO - 10.3791/72056 AN - PMID:42612115 ER -
This study evaluated the effectiveness and cost-effectiveness of Internet-based pharmaceutical care (IPC) incorporating patient-reported outcomes (PROs) in postoperative patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD). A cohort study was conducted at Fuwai Yunnan Hospital between July 2018 and June 2025. Patients received IPC interventions consisting of WeChat-based health education and PRO assessments using the EuroQol EQ-5D-3L and medication compliance questionnaires. A Markov cohort model with a 26-cycle (52-year) horizon was applied to assess the long-term economic value of IPC-PROs. A total of 657 PAH-CHD patients were enrolled, including 422 patients in the IPC group and 235 in the control group. At 90 days post-surgery, the mean pulmonary arterial pressure in the IPC group was significantly lower than that in the control group (33.07 ± 21.62 mmHg vs. 50.17 ± 26.35 mmHg, p. < 0.05). The postoperative health utility improved from 0.6762 to 0.9770 following IPC intervention, while medication compliance scores remained near-perfect throughout the 24-month follow-up period. The Markov cohort simulation demonstrated that the IPC group achieved a gain of 17.0 quality-adjusted life years (QALYs) at a cost of ¥156.87 per patient, resulting in an incremental cost-effectiveness ratio (ICER) of ¥184.11/QALY, which was substantially below the willingness-to-pay threshold of ¥202,800. These findings indicate that IPC integrated with PROs is an effective and cost-effective strategy for improving postoperative outcomes in PAH-CHD patients in Yunnan Province, China.